LA
PCRX icon

Lee Ainslie’s Pacira BioSciences PCRX Stock Holding History

Lee Ainslie’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,823
Closed -$233K – 448
2023
Q2 		$233K Buy
+5,823
New +$241K 0.01% 380
2021
Q3 		– Sell
-1,108
Closed -$67K – 761
2021
Q2 		$67K Buy
+1,108
New +$70.1K ﹤0.01% 589
2020
Q2 		– Sell
-48,159
Closed -$1.61M – 648
2020
Q1 		$1.61M Sell
48,159
-53,060
-52% -$2.2M 0.03% 217
2019
Q4 		$4.58M Sell
101,219
-71,161
-41% -$3.02M 0.07% 144
2019
Q3 		$6.56M Buy
+172,380
New +$6.88M 0.1% 88
2016
Q2 		– Sell
-1,610,932
Closed -$85.3M – 147
2016
Q1 		$85.3M Buy
+1,610,932
New +$94.2M 1.35% 27

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Lee Ainslie's PCRX Position: Q3 2023 in Review

Lee Ainslie sold out of Pacira BioSciences (PCRX) in Q3 2023, closing a stake of 5,823 shares — an estimated $233K sold.

Lee Ainslie first reported a position in PCRX in Q1 2016 and held it in 6 quarters. The position peaked at $85.3M in Q1 2016. 261 funds tracked by Wall St. Rank hold PCRX as of Q3 2023.

  • Lee Ainslie reported no remaining Pacira BioSciences position as of Q3 2023 after selling out during the quarter.
  • Lee Ainslie sold 5,823 Pacira BioSciences shares in Q3 2023, an estimated $233K.
  • Lee Ainslie first reported a position in Pacira BioSciences in Q1 2016 and held it in 6 quarters.
  • Lee Ainslie's Pacira BioSciences position peaked at $85.3M in Q1 2016.
  • 261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2023.

Based on Maverick Capital's 13F filing for Q3 2023, filed 14 Nov 2023.